APF530

Known as: APF-530 
A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
02420092016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AIM APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy… (More)
  • table 1
  • figure 2
  • table 2
  • figure 3
  • table 4
Is this relevant?
2016
2016
APF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h) chemotherapy… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND A phase 3 trial in patients with cancer who received chemotherapy has shown that subcutaneous (SC) APF530, a sustained… (More)
Is this relevant?
2015
2015
BACKGROUND APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to… (More)
Is this relevant?
2015
2015
BACKGROUND Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Subcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0–24 h) and delayed (24–120 h… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
Is this relevant?
2014
2014
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of… (More)
  • figure 1
  • figure 3
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy… (More)
  • figure 1
  • figure 3
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
BACKGROUND Regulatory concern about potential QT-interval prolongation by serotonin-receptor antagonist antiemetics prompted… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2009
2009
9627 Background: APF530 is a polymeric formulation of granisetron providing sustained drug release over 5 days. Two doses (5 and… (More)
Is this relevant?